journal article·2023-01-24

Nano-Formulation of Antioxidants as Effective Inhibitors of γD-Crystallin Aggregation

Amrita Dawn, Vishakha Goswami, Sameer Sapra, Shashank Deep

Langmuir· Volume 39· Issue 3
Publisher page

Abstract

The aggregation of crystallin proteins is related to cataracts and age-related macular degeneration. Apart from surgical replacement of the cataract lens, no other alternative treatment is available till date for this ailment. In the current work, we carried out an in-depth investigation of the effect of polyphenol-loaded nano-formulations on the aggregation of γD-crystallin. At first, the protein was allowed to form amorphous aggregates under denaturing conditions. Several polyphenols were then tried to inhibit the aggregation of the protein. Among the polyphenols tested, resveratrol and quercetin were found to be the most effective. Since polyphenols are prone to degradation, they were encapsulated in chitosan nanoparticles in order to provide ambient conditions for them to function effectively. The loading efficiency and polyphenol release kinetics were subsequently tested. Finally, the efficacy of resveratrol/quercetin-loaded chitosan nano-particles as inhibitors of γD-crystallin aggregation was confirmed in a series of experiments demonstrating the potency of the system in the prospective therapeutic intervention of eye ailments concerning self-assembly of γD-crystallin proteins.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Connexins and lens biology · Advanced Glycation End Products research · Biochemical effects in animals

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi110016, Delhi, India

Funding

Department of Biotechnology, Ministry of Science and Technology, India · Indian Institute of Technology Delhi

References (56)

Show source-provided references
1. 10.1038/302415a010.1038/302415a0 ↗
2. 10.1021/acs.accounts.0c0001410.1021/acs.accounts.0c00014 ↗
3. Oyster C. W. · 1999 · 649
4. 10.1016/j.exer.2004.12.00710.1016/j.exer.2004.12.007 ↗
5. 10.1016/S1568-1637(02)00012-010.1016/S1568-1637(02)00012-0 ↗
6. 10.1073/pnas.22255189910.1073/pnas.222551899 ↗
7. 10.1001/archopht.116.5.65310.1001/archopht.116.5.653 ↗
8. 10.1016/j.ophtha.2014.12.03710.1016/j.ophtha.2014.12.037 ↗
9. 10.1093/emboj/cdf60910.1093/emboj/cdf609 ↗
10. 10.1016/S0140-6736(17)30544-510.1016/S0140-6736(17)30544-5 ↗
11. 10.1016/S2214-109X(20)30489-710.1016/S2214-109X(20)30489-7 ↗
12. 10.1016/s0959-440x(99)00048-210.1016/s0959-440x(99)00048-2 ↗
13. 10.1016/s0022-2836(83)80232-010.1016/s0022-2836(83)80232-0 ↗
14. 10.1016/s0079-6107(98)00032-710.1016/s0079-6107(98)00032-7 ↗
15. 10.1016/j.pbiomolbio.2003.11.01210.1016/j.pbiomolbio.2003.11.012 ↗
16. 10.1016/j.molmed.2012.03.00510.1016/j.molmed.2012.03.005 ↗
17. 10.1110/ps.022550310.1110/ps.0225503 ↗
18. 10.1021/acschemneuro.9b0067710.1021/acschemneuro.9b00677 ↗
19. 10.1042/BCJ2019070510.1042/BCJ20190705 ↗
20. 10.1080/07391102.2020.177570110.1080/07391102.2020.1775701 ↗
21. 10.1016/j.saa.2021.12002310.1016/j.saa.2021.120023 ↗
22. 10.3389/fnut.2018.0008710.3389/fnut.2018.00087 ↗
23. 10.4161/oxim.2.5.949810.4161/oxim.2.5.9498 ↗
24. 10.1002/jbm.a.3649310.1002/jbm.a.36493 ↗
25. 10.1074/jbc.M40475120010.1074/jbc.M404751200 ↗
26. 10.1038/srep2851110.1038/srep28511 ↗
27. 10.1016/j.preteyeres.2010.08.00210.1016/j.preteyeres.2010.08.002 ↗
28. 10.1211/jpp.58.2.000410.1211/jpp.58.2.0004 ↗
29. 10.3390/polym1102030410.3390/polym11020304 ↗
30. 10.1016/j.ejpb.2007.09.00910.1016/j.ejpb.2007.09.009 ↗
31. 10.1016/j.arabjc.2020.10.01910.1016/j.arabjc.2020.10.019 ↗
32. 10.3390/polym1311171710.3390/polym13111717 ↗
33. 10.1155/2013/65389210.1155/2013/653892 ↗
34. Patil J. S. · Dig. J. Nanomater. Biostructures · 2010 · 5 · 241
35. 10.1063/5.000367710.1063/5.0003677 ↗
36. 10.1002/app.3178710.1002/app.31787 ↗
37. 10.1016/j.jmb.2010.05.06710.1016/j.jmb.2010.05.067 ↗
38. 10.1002/pro.29610.1002/pro.296 ↗
39. 10.1016/j.pbiomolbio.2014.05.00210.1016/j.pbiomolbio.2014.05.002 ↗
40. 10.1016/j.neuro.2009.08.01310.1016/j.neuro.2009.08.013 ↗
41. 10.1248/bpb.b18-0032810.1248/bpb.b18-00328 ↗
42. 10.1007/s00417-014-2604-810.1007/s00417-014-2604-8 ↗
43. 10.1016/S1995-7645(14)60307-210.1016/S1995-7645(14)60307-2 ↗
44. 10.1021/acs.biochem.6b0057810.1021/acs.biochem.6b00578 ↗
45. 10.1002/chem.20200202710.1002/chem.202002027 ↗
46. Subathra Devi C. S. · Int. J. PharmTech Res. · 2015 · 7 · 654
47. 10.3390/molecules2211197510.3390/molecules22111975 ↗
48. 10.3109/10717544.2014.92416710.3109/10717544.2014.924167 ↗
49. 10.1021/acs.jafc.8b0457110.1021/acs.jafc.8b04571 ↗
50. 10.7324/JAPS.2015.5070110.7324/JAPS.2015.50701 ↗
51. Sharma, M. A.; Sameer, P. M. D.; Alam, I. N.; Rajalakshmi, A. N.Pharmaceutical Sciences Formulation and Evaluation of Quercetin Nanoparticles Using Low Molecular Chitosan by Qbd Approach. 2021, 10 (2), 1–18.
52. 10.3389/fphar.2018.0082610.3389/fphar.2018.00826 ↗
53. 10.1016/j.biopha.2021.11197010.1016/j.biopha.2021.111970 ↗
54. 10.1016/j.foodhyd.2017.01.04110.1016/j.foodhyd.2017.01.041 ↗
55. 10.3390/molecules2520461310.3390/molecules25204613 ↗
56. 10.1007/s10311-017-0660-010.1007/s10311-017-0660-0 ↗